HighPoint Advisor Group LLC Trims Stock Position in Kenvue Inc. $KVUE

HighPoint Advisor Group LLC trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 61.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 18,092 shares of the company’s stock after selling 29,197 shares during the period. HighPoint Advisor Group LLC’s holdings in Kenvue were worth $294,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. BI Asset Management Fondsmaeglerselskab A S grew its holdings in Kenvue by 76.8% in the third quarter. BI Asset Management Fondsmaeglerselskab A S now owns 137,389 shares of the company’s stock valued at $2,230,000 after purchasing an additional 59,669 shares during the period. Equity Investment Corp boosted its holdings in shares of Kenvue by 5.5% in the 3rd quarter. Equity Investment Corp now owns 5,164,933 shares of the company’s stock valued at $83,827,000 after purchasing an additional 268,763 shares during the last quarter. Machina Capital S.A.S. grew its stake in shares of Kenvue by 7.3% during the 3rd quarter. Machina Capital S.A.S. now owns 130,338 shares of the company’s stock valued at $2,115,000 after buying an additional 8,907 shares during the period. Hantz Financial Services Inc. increased its holdings in shares of Kenvue by 157.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 2,850 shares of the company’s stock worth $46,000 after buying an additional 1,742 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC raised its position in shares of Kenvue by 18.2% in the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 21,693 shares of the company’s stock worth $352,000 after buying an additional 3,335 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity at Kenvue

In other news, Director Jeffrey C. Smith bought 3,200,000 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was acquired at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the purchase, the director owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.17% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $18.12 on Monday. The business’s 50-day simple moving average is $17.24 and its 200 day simple moving average is $17.83. The company has a market cap of $34.72 billion, a P/E ratio of 24.16 and a beta of 0.59. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be paid a dividend of $0.2075 per share. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft set a $18.00 target price on Kenvue in a report on Friday, October 24th. Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Canaccord Genuity Group reissued a “hold” rating and set a $15.00 target price (down previously from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. Edward Jones lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Four investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and an average price target of $19.46.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.